#Canada #Vancouver #WAT Medical #EmeTerm #Postoperative Nausea

WAT Medical's EmeTerm: A Game Changer in PONV Management

WAT Medical is making headlines in the medical field with its groundbreaking publication in the esteemed journal, JAMA Surgery, showcasing the efficacy of the EmeTerm wearable device. This innovative tool utilizes transcutaneous electrical acupoint stimulation to provide patients suffering from moderate to severe postoperative nausea and vomiting (PONV) an alternative to traditional medications.

The study involved a randomized clinical trial enrolling 232 female participants who developed PONV following thyroidectomy or anterior cervical surgery. The trial compared the outcomes of the EmeTerm device against metoclopramide, a commonly prescribed antiemetic, highlighting significant improvements in nausea control among those using EmeTerm.

Key Findings from the Trial

The primary focus of the trial was to assess the two-hour remission rate of PONV. Results showed that the EmeTerm wristband delivered a striking remission rate of 77.6%, in comparison to just 55.2% for those treated with metoclopramide (P < 0.001). This compelling evidence underscores the superiority of EmeTerm in offering rapid and sustained relief from postoperative nausea.

Additionally, participants using the EmeTerm device experienced a significantly lower relapse rate within 24 hours post-surgery at 12.2%, compared to the alarming 56.3% seen in the metoclopramide group (P < 0.001). No adverse device-related serious events were reported during the study, pointing to a favorable safety profile.

A Shift Towards Non-Pharmacological Approaches

The findings from this robust clinical trial reflect a significant trend towards incorporating non-pharmaceutical solutions in perioperative care. By utilizing devices like EmeTerm, healthcare providers can enhance patient autonomy and minimize the side effects often associated with medications, leading to better overall treatment experiences and improved recovery outcomes.

Having already garnered multiple international regulatory approvals, including from the U.S. FDA, Health Canada, and Australia's TGA, EmeTerm stands as a testament to WAT Medical Enterprise Ltd.'s commitment to evidence-based innovations in healthcare.

Conclusion: The Future of Nausea Management

Publication in a high-impact journal like JAMA Surgery signifies the meticulous nature and importance of this research. It emphasizes not only the efficiency of EmeTerm as a therapeutic option for managing PONV but also its potential to revolutionize postoperative care. As clinical evidence continues to pile up, EmeTerm is gaining traction among clinicians and hospitals worldwide, indicating a promising future for patients struggling with nausea management during recovery.

In an era where patient-centered care is paramount, WAT Medical's EmeTerm is leading the charge towards more effective and safer treatment methods. With this device, patients can look forward to a smoother recovery process, free from the burdens of nausea and vomiting.